KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Restructuring Costs: 2017-2025

Historic Restructuring Costs for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $143,000.

  • Amneal Pharmaceuticals' Restructuring Costs fell 16.86% to $143,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 12.90%. This contributed to the annual value of $2.4 million for FY2024, which is 34.65% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Restructuring Costs is $143,000, which was down 86.04% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Restructuring Costs ranged from a high of $7.3 million in Q4 2021 and a low of $82,000 during Q2 2023.
  • Moreover, its 3-year median value for Restructuring Costs was $493,000 (2024), whereas its average is $531,091.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Restructuring Costs plummeted by 98.51% in 2022, and later spiked by 365.45% in 2025.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Restructuring Costs stood at $7.3 million in 2021, then tumbled by 98.51% to $109,000 in 2022, then grew by 4.59% to $114,000 in 2023, then spiked by 332.46% to $493,000 in 2024, then dropped by 16.86% to $143,000 in 2025.
  • Its Restructuring Costs was $143,000 in Q3 2025, compared to $1.0 million in Q2 2025 and $571,000 in Q1 2025.